Status:
RECRUITING
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Lead Sponsor:
CHDI Foundation, Inc.
Conditions:
Huntington's Disease
Eligibility:
All Genders
18+ years
Brief Summary
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while al...
Detailed Description
The primary objective of Enroll-HD is to develop a comprehensive repository of prospective and systematically collected clinical research data (demography, clinical features, family history, genetic c...
Eligibility Criteria
Inclusion
- Carriers: This group comprises the primary study population and consists of individuals who carry the HD gene expansion mutation.
- Controls: This group comprises the comparator study population and consists of individuals who do not carry the HD expansion mutation.
- These two major categories can be further subdivided into six different subgroups of eligible individuals:
- Manifest/Motor-manifest HD: Carriers with clinical features that are regarded in the opinion of the investigator as diagnostic of HD.
- Pre-Manifest/-Motor-manifest HD: Carriers without clinical features regarded as diagnostic of HD.
- Genotype Unknown: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has not undergone predictive testing for HD and therefore has an undetermined carrier status.
- Genotype Negative: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has undergone predictive testing for HD and is known not to carry the HD expansion mutation.
- Family Control: Family members or individuals not related by blood to carriers (e.g., spouses, partners, caregivers).
- Community Controls: Individuals unrelated to HD carriers who did not grow up in a family affected by HD. Data collected from community controls will be used for generation of normative data for sub-studies.
- Participant status will be captured in the study database using 2 variables: 1) Investigator Determined Status: this will be based on clinical signs and symptoms and genotyping performed as part of medical care, and will be updated at every visit; and 2) Research Genotyping Status: this will be based on genotyping conducted as part of Enroll-HD study procedures. Based on research genotyping, participants will be reclassified under this variable from Genotype Unknown to 'Carriers' or 'Controls'. Investigators and participants will be blinded to this reclassification.
Exclusion
- Individuals who do not meet inclusion criteria,
- Individuals with choreic movement disorders in the context of a negative test for the HD gene mutation.
- For Community Controls: those individuals with a major central nervous system disorder will be excluded (e.g. stroke, Parkinson's disease, multiple sclerosis, etc.).
- Participants under 18 may be eligible to participate (if they have juvenile-onset HD).
Key Trial Info
Start Date :
July 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2062
Estimated Enrollment :
35000 Patients enrolled
Trial Details
Trial ID
NCT01574053
Start Date
July 1 2012
End Date
January 1 2062
Last Update
February 28 2024
Active Locations (183)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35294
2
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States, 85013
3
University of California - Irvine Medical Center
Irvine, California, United States, 92697
4
Loma Linda Medical Center
Loma Linda, California, United States, 92354